ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 996,64
0,49%
Dow Jones
38 852,27
0,46%
DAX
18 175,21
1,01%
Brent Oil
83,475
0,42%
Bitcoin
63 491,90
-0,79%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Prime Medicine Inc (PRME)

  7. Prime Medicine Inc (PRME) Actualités

PRME Prime Medicine Inc

5,40
-0,19 (-3,40%)
Après les heures de négociation
Dernière mise à jour : 23:15:45
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Prime Medicine Inc PRME NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,19 -3,40% 5,40 23:15:45
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
5,65 5,39 5,77 5,40 5,59
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
01/5/202414:00GLOBEPrime Medicine to Participate in the 27th Annual Milken..
29/4/202413:00GLOBEPrime Medicine Announces FDA Clearance of Investigational..
23/4/202414:00GLOBEPrime Medicine to Present Preclinical Data Demonstrating..
01/3/202414:09EDGAR2Form S-8 - Securities to be offered to employees in employee..
01/3/202414:04EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
01/3/202414:01EDGAR2Form 8-K - Current report
01/3/202414:00GLOBEPrime Medicine Reports Full Year 2023 Financial Results and..
28/2/202414:00GLOBEPrime Medicine to Participate in Upcoming Investor..
23/2/202423:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202423:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202403:31EDGAR2Form SC 13D - General statement of acquisition of beneficial..
20/2/202423:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202422:01GLOBEPrime Medicine Announces Closing of Upsized Public Offering..
16/2/202412:23EDGAR2Form 8-K - Current report
16/2/202412:17EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
15/2/202405:50GLOBEPrime Medicine Announces Pricing of Upsized Public Offering
15/2/202403:57EDGAR2Form FWP - Filing under Securities Act Rules 163/433 of free..
14/2/202423:27EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
14/2/202422:12EDGAR2Form 8-K - Current report
14/2/202422:05GLOBEPrime Medicine Announces Proposed Public Offering of Common..
25/1/202414:00GLOBEPrime Medicine Receives Up to $15 Million from Cystic..
08/1/202414:01EDGAR2Form 8-K - Current report
05/1/202423:03EDGAR2Form 8-K - Current report
05/1/202414:15EDGAR2Form 8-K - Current report
05/1/202414:00GLOBEPrime Medicine Appoints Allan Reine, M.D., as Chief..
02/1/202414:00GLOBEPrime Medicine to Present at 42nd Annual J.P. Morgan..
14/11/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
08/11/202314:00GLOBEPrime Medicine to Present at Upcoming Investor Conferences
03/11/202322:23EDGAR2Form S-3 - Registration statement under Securities Act of..
03/11/202322:09EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/11/202321:06EDGAR2Form 8-K - Current report
03/11/202321:01GLOBEPrime Medicine Reports Third Quarter 2023 Financial Results..
27/10/202312:00GLOBEPrime Medicine Presents First-ever Prime Editing Data in..
24/10/202313:30GLOBEPrime Medicine Presents First In Vivo Proof-of-Concept Prime..
17/10/202314:00GLOBEPrime Medicine to Highlight Positive Preclinical..
19/9/202314:00GLOBEPrime Medicine to Present at Upcoming Investor Conferences
31/8/202314:00GLOBEPrime Medicine to Present at Upcoming Investor Conferences
07/8/202322:09EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/8/202322:04EDGAR2Form 8-K - Current report
07/8/202322:01GLOBEPrime Medicine Reports Second Quarter 2023 Financial Results..
22/6/202314:00GLOBEPrime Medicine and Cimeio Therapeutics Announce Research..
31/5/202314:00GLOBEPrime Medicine to Present at Investor Conferences in June
17/5/202322:05GLOBEPrime Medicine to Present at Virtual Investor Conferences in..
17/5/202312:00GLOBEPrime Medicine to Present New Preclinical Data Highlighting..
11/5/202314:00GLOBEPrime Medicine Reports First Quarter 2023 Financial Results..

Dernières Valeurs Consultées

NASDAQ
PRME
Prime Medicine
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés